Last reviewed · How we verify
NCT06600399: PSMA，ASL，PET
Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma
trial testing glioblastoma in Glioblastoma in 26 participants. Completed in 29 February 2024.
29 February 2024
Quick facts
| Lead sponsor | Lanzhou University Second Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 26 |
| Start date | 1 October 2022 |
| Primary completion | 29 February 2024 |
| Estimated completion | 29 February 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- glioblastoma
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
Sponsor
Lanzhou University Second Hospital
Who can join
18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluating the relationship between prostate-specific membrane antigen positron emission tomography and arterial spin labeling perfusion imaging, and the correlation with prostate-specific membrane antigen expressed on glioblastoma microvascular.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06600399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Lanzhou University Second Hospital trials
Trials by the same sponsor.
- NCT07492147 — Effect of Negative Pressure Suction on Fluid Absorption and Infection in Flexible Ureteroscopy · recruiting
- NCT06945432 — Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection · completed
- NCT06657755 — Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients · completed
- NCT07299253 — Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06 · EARLY_PHASE1 · completed
- NCT06206642 — Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06600399 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lanzhou University Second Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06600399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing